Related Experiment Video
Updated: Aug 29, 2025
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
36.8K
Donanemab removes Alzheimer's plaques: what is special about its target?
Deborah O T Alawode1, Amanda J Heslegrave1, Nick C Fox2
1Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, UCL, London, UK; UK Dementia Research Institute at UCL, UCL, London, UK.
The Lancet. Healthy Longevity
|September 13, 2022
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
249
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
249
01:26Alzheimer's Disease: Overview
640
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
640